Skip to main content
. 2018 Aug 24;9(66):32580–32592. doi: 10.18632/oncotarget.25953

Figure 2. HELLS is overexpressed in human and mouse osteosarcoma.

Figure 2

(A) The Cancer Genome Atlas data of RNA-Seq by Expectation-Maximation (RSEM) values from 263 human sarcoma samples (red) compared to normal control (blue) show a 4.27-fold increase in HELLS mRNA expression. (B–C) RT-qPCR analysis of HELLS mRNA expression in (B) 143B, SJSA-1, SaOS-2 and U-2 OS osteosarcoma cell lines and (C) patient-derived xenografts (PDX1-5), normalized to mesenchymal stem cells (MSC1 and MSC2) (D) Western blot detection of HELLS in osteosarcoma cell lines and PDXs show increased protein levels compared to two lineage progenitor controls, MSCs and human osteoblasts (hOB). Actin used as loading control. Band intensities were quantified by densitometry and normalized to MSC. (E) Western blot detection of HELLS in a mouse p53/Rb1 DKO tumor.